Assenagon Asset Management S.A. Trims Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Assenagon Asset Management S.A. trimmed its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 21.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,945,225 shares of the biotechnology company’s stock after selling 1,088,946 shares during the period. Assenagon Asset Management S.A. owned about 1.75% of ADMA Biologics worth $17,832,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ADMA. State Street Corp raised its stake in shares of ADMA Biologics by 217.9% in the 3rd quarter. State Street Corp now owns 9,423,422 shares of the biotechnology company’s stock valued at $22,899,000 after acquiring an additional 6,459,197 shares during the period. Millennium Management LLC raised its stake in shares of ADMA Biologics by 206.7% in the 4th quarter. Millennium Management LLC now owns 5,296,781 shares of the biotechnology company’s stock valued at $20,552,000 after acquiring an additional 3,569,778 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $12,658,000. Point72 Asset Management L.P. purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $7,725,000. Finally, Stonepine Capital Management LLC raised its stake in shares of ADMA Biologics by 38.8% in the 4th quarter. Stonepine Capital Management LLC now owns 6,940,000 shares of the biotechnology company’s stock valued at $26,927,000 after acquiring an additional 1,940,000 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of research analyst reports. Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. HC Wainwright reaffirmed a “buy” rating and set a $7.50 target price (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday. Finally, Mizuho upped their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.88.

ADMA Biologics Trading Up 3.7 %

NASDAQ ADMA opened at $6.74 on Thursday. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $6.75. The stock has a market capitalization of $1.54 billion, a PE ratio of -51.85 and a beta of 0.43. The firm has a 50 day moving average of $5.59 and a two-hundred day moving average of $4.46.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.3 EPS for the current fiscal year.

Insider Activity

In other news, Director Steve Elms sold 183,008 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the transaction, the director now owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 639,895 shares of company stock worth $3,927,169. Corporate insiders own 5.90% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.